With $27B plan to build 4 new plants, Eli Lilly doubles down on US drug manufacturing
Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than the last—the company’s spree has begged the question: What will they do | At a press conference in Washington,
Eli Lilly to build 4 more manufacturing sites in US
Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will produce active pharmaceutical ingredients (APIs), which are key ingredients in drugs.
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
5don MSN
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...
Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...
The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, significantly lower than the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback